16017-69-9Relevant articles and documents
RETINOID COMPOUND AND PHARMACEUTICAL COMPOSITION
-
, (2020/04/17)
PROBLEM TO BE SOLVED: To provide a novel retinoid compound that is low in teratogenicity, and a pharmaceutical composition containing said retinoid compound. SOLUTION: Provided are a retinoid compound which is a compound represented by the following formula (1) or a salt thereof, and a pharmaceutical composition containing said retinoid compound. In the formula, R1 represents a halogen atom, and R2 and R3 each independently represent a silyl group. SELECTED DRAWING: None COPYRIGHT: (C)2020,JPOandINPIT
Discovery of pyrido[3,4-g]quinazoline derivatives as CMGC family protein kinase inhibitors: Design, synthesis, inhibitory potency and X-ray co-crystal structure
Esvan, Yannick J.,Zeinyeh, Wael,Boibessot, Thibaut,Nauton, Lionel,Théry, Vincent,Knapp, Stefan,Chaikuad, Apirat,Loa?c, Nadège,Meijer, Laurent,Anizon, Fabrice,Giraud, Francis,Moreau, Pascale
, p. 170 - 177 (2016/05/09)
The design and synthesis of new pyrido[3,4-g]quinazoline derivatives is described as well as their protein kinase inhibitory potencies toward five CMGC family members (CDK5, CK1, GSK3, CLK1 and DYRK1A). The interest for this original tricyclic heteroaroma
Aryl or heteroaryl amides of tetrahydronaphthalene, chroman, thichroman and 1,2,3,4-tetrahydroquinolinecarboxlic acids, having an electron withdrawing substituent in the aromatic or heteroaromatic moiety, having retinoid-like biological activity
-
Page column 20, (2010/11/29)
Compounds of the formula wherein the symbols have the meaning defined in the specification have retinoid-like biological activity.